Inhibition of human hepatocellular carcinoma cell proliferation by galactose receptor mediated c-myc antisense oligonucleotide

AIM: To evaluate the inhibitory effect of galactose (Gal)-polyethyleneimine (PEI)-c-myc antisense oligodeoxynucleotide (ASODN) complex on proliferation of human hepatocellular carcinoma cells. METHODS: Human hepatocellular carcinoma cell line Bel-7402 was treated with Gal-PEI-ASODN complex. Cell proliferation was tested by trypan blue dye at different time points and with various concentrations of ASODN treatment. Cell morphology was observed under inverted microscope, cell hypodiploid percentage was analyzed by flow cytometry and cell ultrastructure was observed through electron microscopy. RESULTS: Compared with ASODN group (20 μmol/L) from 0 h to 96 h, Gal-PEI-ASODN complex (with ASODN 0.75 μmol/L) significantly suppressed Bel-7402 cells proliferation, the ASODN concentration within Gal-PEI-ASODN complex and time course acquired were significantly lower and shorter, respectively. Incubated with pure ASODN at different concentrations for 72 hours, cell proliferation was inhibited and IC₅₀ was 20.9 μmol/L; while mediated with galactose receptor for 48 hours, ASODN significantly inhibited cell proliferation and IC₅₀ was only 0.294 μmol/L, the inhibitory efficacy of ASODN enhanced 70.9 folds. While Bel-7402 cells were incubated with Gal-PEI-ASODN complex for 48 hours, cell hypodiploid percentage was much higher than ASODN groups and cell apoptosis was seen under electron microscopy. CONCLUSIONS: Galactose receptor mediated ASODN delivery may significantly increase proliferation inhibition efficacy on Bel-7402 cells.     

Effect of protein kinase C-α antisense oligonucleotide on cell cycle of CNE-2Z cells

AIM:To observe the effect of protein kinase C-α(PKCα)antisense oligonucleotide on cell growth, cell cycle and the expression of cyclin E in human poor-differentiated nasopharyngeal carcinoma(NPC) cell line CNE-2Z. METHODS:Antisense PKCα was transfected by cationic liposome(LP) in CNE-2Z cells to analyze the cell growth and cell cycle by MTT colorimetric assay and flow cytometry, respectively. Moreover, the expression of cyclin E was determined by immunocellularchemistry and scanning the result of dot-blotting. RESULTS:①With the concentration of antisense PKCα increasing, the relative cell growth index was decreased gradually(P＜0.01). ②After treated with antisense PKCα, the percentage of cells in G₁ phase enhanced(P＜0.05). ③Compared with the control group, the expressing intensity of cyclin E reduced in antisense PKCα group, and the expression of cyclin E decreased to 66.5%±18.4％(P＜0.05) of the control by scanning quantitative analysis. CONCLUSION:These results indicated that antisense PKCα may inhibit cell growth in CNE-2Z via suppressing the expression of cyclin E and hindering cell process in G₁ phase.     

Antiproliferative effect of c-myc antisense oligonucleotide in rat thymus lymphocytes

AIM: To observe the antiproliferative effect of c-myc antisense oligonucleotide in rat thymus lymphocytes. METHODS: Rat thymus lymphocytes were separated by Ficoll-Urografin density gradient centrifugation. Lipofectin was used to introduce antisense, sense and mismatched oligonucleotides for c-myc to rat thymus lymphocytes. The antiproliferative effect was assayed by incorporation of [³H]-TdR and MTS cell proliferation assay. TR-PCR was used to detect the expression of c-myc mRNA. RESULTS: c-myc antisense oligonucleotide inhibited ratthymus lymphocytes proliferation[(0.14±0.03)A vs(0.32±0.16)A,P<0.05],but this ef ect had no relationship with the concentration of c-myc antisense oligonucleot ide.c-myc antisense oligonucleotide decreased the expression of c-myc mRNA in rat thymus lymphocytes. CONCLUSION: c-myc antisense oligonucleotide inhibited rat thymus lymphocyte proliferation.     

Inhibitory effect of survivin-siRNA on prostatic subcutaneous xenografts in nude mice

AIM: To investigate the inhibitory effect of survivin-siRNA recombinant plasmid on prostate cancer xenografts. METHODS: Prostatic cancer DU145 cells were cultured and subcutaneously injected into nude mice. When the tumor grew to 8 mm in diameter, it was aseptically removed and divided into about 2 mm blocks through surgery and subcutaneously implanted into another nude mice. After the prostatic cancer xenograft model was reconstructed, the mice were treated with survivin-siRNA plasmid and control scrambled siRNA plasmid using electric transfection method. The tumor growth curve was plotted and the inhibitory rate was calculated. HE staining, immunohistochemical staining and TUNEL assay were applied to observe the effect of survivin-siRNA on the xenografts. RESULTS: The prostatic cancer xenograft model was successfully constructed in vivo. Compared with mock and scrambled siRNA groups, transfection of survivin-siRNA recombinant plasmid obviously inhibited the tumor growth with the inhibitory rates of 61.81% and 62.87%, respectively. Compared with both controls, survivin-siRNA depressed the protein expression of survivin and promoted the cell apoptosis. CONCLUSION: Survivin-siRNA recombinant plasmid significantly inhibits the growth of prostatic tumor xenografts by inhibiting the protein expression of endogenous survivin and promoting cell apoptosis.     

Inhibitory effect of survivin antisense oligodeoxyribonucleotide combined with DDP in nude mice bearing human osteosarcoma xenograft

AIM:To investigate the feasibility and its mechanisms of improving therapeutic effect by antisense gene therapy combined with chemotherapy in osteosarcoma. METHODS:The human osteosarcoma implanted tumor model in the nude mice was established. By intratumoral injection and abdominal cavity administration, the tumor bearing mice were treated with survivin ASODN in combination with diamminedichloroplatinum (DDP) for a week. Comparison with each single-agent therapy and control group was performed in aspects such as tumor growth condition, pathological changes of tumor tissues;survivin protein expression in tumor tissues by immunohistochemistry, survivin mRNA expression levels by RT-PCR method and tumor apoptosis by Tdt-mediated dUTP nick end labeling (TUNEL). RESULTS:All nude mice survived the therapy. As compared with the control group, the antisense gene therapy group presented synchronous decrease in survivin mRNA and protein expression;all therapy group displayed tumor growth inhibition and cell apoptosis with different extent;while in contrast to single-agent therapy group, the combined therapy group showed stronger inhibition of tumor growth and abundant tumor cell apoptosis with the highest apoptotic rate. CONCLUSION:Synergistic effect was achieved by combination of DDP with ASODN that may overcome drug resistant of DDP and the combined strategy may shed new light on the cancer therapy.     

Inhibitory effect of different target-side antisense oligonucleotides on bFGF expression in SWO-38 cells

AIM:Three different antisense oligonucleotides complementary to basic fibroblast growth factor (bFGF) mRNA were compared in inhibitory effect on gene targeted expression.METHODS:After transfecting bFGF antisense oligonucleotides (asODN) into SWO-38 cells by lipofectin, the proliferation of cells was identified by MTT method, apoptosis was examined by flow cytometric cell cycle analysis and the expression levers of bFGF were detected by Western-blotting.RESULTS:There were 49%, 33%, 51% inhibition of cell growth and 35%, 27%, 18% cell apoptosis after asODN1, asODN2 and asODN3 treatment.In addition, the decrease in bFGF protein was 63%, 42%, 11%, respectively.CONCLUSION:The data suggeste that asODN1 is a potent target to bFGF mRNA, which inhibits cell growth and induces apoptosis in SWO-38 cells.     

Advanced studies on antisense oligonucleotide treatment and target-gene of leukemia

The oncogene expression and growth of leukemic cells could be inhibited by antisense oligonucleotide.The selection of target genes is the key step in the research of antisense oligonucleotide on leukemia.The art icle would review the status and prospect of some target genes of leukemia in the investigation of antisense oligonucleotide.     

Changes of plasma endostatin levels in nude mice bearing human nasopharyngeal carcinoma

AIM: To approach the changes of endostatin levels in BALB/c nude mice bearing human nasopharyngeal carcinoma(NPC) in different period (5, 10, 20, 30 and 40 days) and the relationship between endostatin and tumor's development. METHODS: BALB/c nude mice bearing NPC was reproduced by hypodermic implantation of human CNE-2 cells into right-side of axillary fossa. The level of plasma endostation was detected, and the weight of isolated tumors was measured. On the basis of the regulation of these changes, their relationships were explored. RESULTS: At 5 days [(137.61±53.41) μg/L] or 10 days [(103.06±17.33) μg/L] endostatin level had no apparent alternation in comparison with control group [(113.56±21.74) μg/L, P>0.05]. At 20, 30 and 40 days concentration of endostatin[(212.80±85.91) μg/L,(293.63±62.53) μg/L, (271.57±32.45) μg/L, respectively] were higher than that of the control group (P<0.05). Along with the development of the tumors, both the levels of endostatin and tumors weight increased. There was a positive correlation between the level of endostatin and tumor weight (r=0.687, P<0.05). CONCLUSION:These results suggested that endostatin links with the development of NPC.     

Induction of apoptosis by c-myc antisense oligonucleotide in osteosarcoma cell MG-63

AIM: To study the induction of apoptosis by c-myc antisense oligonucleotide in osteosarcoma cell (MG-63).METHODS: The designed c-myc antisense oligonucleotide fragment was transfected into human osteosarcoma MG-63 cells. The cell growth and apoptosis were measured by the methods of MTT, FCM, HE staining and transmission electron microscopy.RESULTS: The results showed that the proliferation of human osteosarcoma MG-63 cells was inhibited and apoptotic rate was 37.92% when treated with c-myc antisense oligonucleotide at the does of 10.0 μmol/L for 48 h. c-myc antisense oligonucleotide (10.0 μmol/L) also inhibited the expression of c-myc protein.CONCLUSION: c-myc antisense oligonucleotide is able to induce apoptosis in human osteosarcoma MG-63 cells.     

Effects of PKC-α asODN and PKA-ⅠasODN on growth and proliferation of the CNE-2Z cells of nasopharyngeal carcinoma

AIM:To investigate the effects of antisense oligonucleotides (asODN) of PKC-α and PKA-Ⅰon growth and proliferation of the CNE-2Z cells.METHODS:The expression of PKC-α and PKA-Ⅰ was observed with immunohistochemistry method. The asODNs of (1)PKC-α, (2)PKA-Ⅰ, (3)PKC-α and PKA-Ⅰ, were transfected into CNE-2Z cells by lipofectin (LP), and a random sequence as a control was used. The cell growth index (GI) and the clone formation rate of CNE-2Z were detected by MTT colorimetric assay and soft agar assy, respectively.RESULTS:The expression of PKC-α or PKA-Ⅰin CNE-2Z in experimental group were both significantly lower than that of control group(P<0.05). The GI and clone formation rates of CNE-2Z cells transfected by PKC-α and PKA-ⅠasODN with concentrations ranging from 0.05 μM to 1.00 μM were lower significantly than that of control groups(P<0.05), and there was a dose-dependent relationship among them. The inhibitory effects of PKC-α and PKA-ⅠasODNs both on the cell growth index (GI) and clone formation rates were more significant than that of control group(P<0.01),and the GI were significantly lower than that of the other experimental groups(P<0.05).CONCLUSION:PKC-α asODN and PKA-ⅠasODN inhibited CNE-2Z growth and proliferation in vitro, and a synergetic inhibitory effect of PKC-α asODN and PKA-ⅠasODN was also observed.     

The anticancer activity of genistein on implanted tumor of human primary gastric carcinoma cells in nude mice

AIM: To investigate the apoptosis of implanted tumor of primary human gastric cancer cells in nude mice induced by genistein and the relation between this apoptosis and expression of bcl-2 and bax.METHODS: Establishing a transplanted tumor model by injecting human primary gastric cancer cells into subcutaneous tissue of nude mice.The different doses of genistein (0.5mg/kg,1mg/kg and 1.5 mg/kg ) were directly injected beside tumor body respectively,for six times at an interval of two days.Then changes of tumor volume were measured continuously and tumor inhibition rate of each group was calculated.We observed the morphologic alteration by electron microscope,measured the apoptotic rate by TUNEL staining method,detected the expression of apoptosis-regulated gene bcl-2 and bax by immunohistochemical staining and RT-PCR.RESULTS: Genistein could significantly inhibit carcinoma growth when it was injected near the carcinoma.Genistein induced implanted tumors cells to undergo apoptosis with apoptotic characteristics by transmission electron microscope.The apoptosis index of above three groups was increased progressively.Positive rate of Bcl-2 protein of above three groups was decreased progressively and positive rate of Bax protein of above three groups was increased progressively by immunohistochemical staining.The density of bcl-2 mRNA decreased progressively and the density of bax mRNA increased progressively with elongation of time by RT-PCR.CONCLUSION: Genistein is able to induce the apoptosis of transplanted tumor cells.This apoptosis may be mediated by down-regulating bcl-2 and up-regulating bax mRNA and its protein.     

Inhibitory effects of LDL-ACM complex on subcutaneous implanted tumors in nude mice()

AIM: In order to evaluate the applicable value of LDL as a targeted vehicle for chemotherapeutic agents, we investigated and compared the inhibitory effects of LDL-ACM complex and free ACM on nude mice's subcutaneous implanted tumors derived from gastric cancer cell lines, SGC-7901 and NKM-45. METHODS: LDL-ACM complex was prepared and the tumor model of nude mice was established by subcutaneous implantation of SGC-7901 and NKM-45. Then, the groups of nude mice developed subcutaneous implanted tumors were received either LDL-ACM complex or free ACM. Subsequently, the tumor size, weight and leukemia cell counts were measured and the rates of tumor-inhibition and the survival were compared among the groups. RESULTS: The inhibitory effects of LDL-ACM complex on the tumors, especially on SGC-7901 implanted tumors were much more obvious than that of free ACM. It was also indicated that the action of LDL-ACM complex was mediated by LDL receptor. CONCLUSION: These results showed that LDL-ACM complex had significant inhibitory effects on the implanted tumors and the effect might be mediated by LDL receptor.     

Expression of miR-125b in pediatric acute myeloid leukemia and the effect of anti-miR-125b oligonucleotide on proliferation of human leukemic cells

AIM: To investigate the expression of miR-125b in pediatric acute myeloid leukemia (AML), and to explore the inhibitory effect of anti-miR-125b oligonucleotide on human leukemic cells. METHODS: The expression of miRNAs in pediatric AML bone marrow cells was analyzed by gene microarray and real-time quantitative PCR. HL-60 cells were transfected with anti-miR-125b, which was complementary to miR-125b in sequence, and the viability of HL-60 cells was measured by CCK-8 assay 24 h, 48 h, 72 h and 96 h after electroporation. RESULTS: The expression levels of miR-125b in the cells of newly diagnosed pediatric AML patients was almost 12 times as high as that in the cells of idiopathic thrombocytopenic purpura cases.However, the decreased levels of miR-125b in the cells of partial remission patients and returned to normal in the cells of completely remission patients were observed. At the same time, the growth rate of the cells treated with anti-miR-125b oligonucleotide was obviously decreased compared with that of control cells. CONCLUSION: miR-125b may take effect as an oncogene in pediatric AML. Anti-miR-125b oligonucleotide may be useful as a new drug for treating pediatric AML.     

Effect of CLCN2 antisense oligonucleotide on U251 cells injury by cisplatin

AIM: To investigate the effect of chloride channel CLCN2 antisense oligonucleotide on the cell injury of malignant U251 glioma cells induced by cisplatin (DDP). METHODS: The experiment was divided into 4 groups: control group (nonsense oligonucleotide), CLCN2 antisense oligonucleotide group, DDP group (DDP＋nonsense oligonucleotide), DDP＋CLCN2 antisense oligonucleotide group. The viability of U251 cells was measured by MTT assay, CLCN2 mRNA level was determined by RT-PCR, cell apoptosis was measured by TUNEL assay. RESULTS: Compared to the control group, the cell viability, CLCN2 and cyclinD1 mRNA decreased in CLCN2 antisense oligonucleotide group, DDP treated group and CLCN2 antisense oligonucleotide with DDP treated group, cells apoptosis increased. Compared to DDP group, the cell viability (P<0.05) and CLCN2 mRNA decreased in CLCN2 antisense oligonucleotide with DDP treated group, and cells apoptosis increased (P<0.01). Compared to CLCN2 antisense oligonucleotide group, CLCN2 mRNA significantly decreased (P<0.01) in CLCN2 antisense oligonucleotide with DDP treated group. CONCLUSION: CLCN2 antisense oligonucleotide inhibits the expression of CLCN2 mRNA in U251 cells. Inhibition of CLCN2 mRNA facilitates the cell injury of U251 cells induced by DDP. The decrease in CLCN2 mRNA is involved in the mechanism of cell injury by DDP.     

Effect of naja naja atra venom on plasmic GSH-PX and catalase of human nasopharyngeal carcinoma bearing nude mice

AIM: To investigate the changes of plasma glutathione peroxidase (GSH-PX) and catalase (CAT) activities in nude mice (NM) bearing human nasopharyngeal carcinoma (NPC) and observe the effect of naja naja atra venom (NNAV) on them. METHODS: Plasma GSH-PX and CAT activities in human NPC bearing NM treated (i.p.) by low, middle or high concentration NNAV solution (1 mg/L, 5 mg/L, 10 mg/L) were determined by colorimetry. RESULTS: Plasma CAT activity (16 450 U/L) in NM bearing tumor group decreased significantly in comparison with the control group (20 680 U/L)(P＜0.05). Plasma GSH-PX activity (27 670 U/L) in NM bearing tumor group had no apparent alteration in comparison with the control group (28 790 U/L)(P＞0.05). Treated by low, middle or high concentration NNAV solution, CAT activities of three NM bearing tumor groups (20 570 U/L, 23 090 U/L, 21 280 U/L) were higher than that of the NM bearing tumor group without NNAV treatment (16 450 U/L) (P＜0.05), and reached to control level (20 680 U/L)(P＞0.05). GSH-PX activities of the three groups (especially high concentration group) were higher than that of the group without NNAV treatment (P＜0.05). CONCLUSION: The antitumor effect of NNAV might be by means of increasing GSH-PX activity and CAT activity in NM bearing human NPC.     

The effect of antisense bcr-abl oligonucleotides on the growth of K562 cells

AIM:To study the effect of bcr- abl gene antisense phosphorothioate oligonucleotides(Aspo) on K562 cell line and explore its significance in chrenic myelogeneous leukemia (CML) gene therapy.METHODS:Cells were exposed to oligomeis, observed by inverted microscope.Cells inhibitory rate were determined by 0.4 trypan blue exclusion . CFU-K562 were cultured in 0.8 % methylcellulose . P210 was measured by flow cytomety RESULTS: K562 cells were treated with Aspo, they still grew in clone state and show antisense sequence specific and dose dependent. When the concentration of Aspo was more than Spznol/L, the growth of cells was inhibited and P210 was down regulated or completely suppressed, and the greatest growth inhibition was at 120h . There was signifi-cant inhibition of cell proliferation in a rang‘cells number from 1×10⁴/mL to 5×10⁴/mL after treatment with 10unol/L Aspo. b2a2 Aspo was also effect on K562 cells which expressing b3a2 mRNA.CONCLUSION: bcr-abl Aspo has a specific growth inhibition effect on K562 cells, and worths further study in CML gene therapy.     

Effects of RNA interference of FABP5 on subcutaneous tumor of human hepatocellular carcinoma cell line HepG 2 transplanted in nude mice

AIM: To investigate the effect of recombinant lentiviral vector for RNA interference (RNAi) on the expression of fatty acid-binding protein 5 (FABP5) gene in hepatocellular carcinoma HepG2 cells and tumor formation in nude mice.METHODS: RNAi lentiviral vector was used in the experiment. Human hepatocellular carcinoma HepG2 cells were divided into 3 groups:the HepG2 cells in experimental group were transfected with the recombinant lentivirirus vector LV-shRNA-FABP5, the cells in negative control group were transfected with a control lentiviral vector LV-shRNA-NC, and the cells in normal control group were without any treatment. The nude mice were randomly divided into 3 groups. The growth of the transplanted tumor cells in the nude mice was observed. The tumor growth curve, volume and weight were determined 4 weeks after the cell inoculation. The expression of FABP5 was detected by real-time PCR, Western blot and immunohistochemical staining.RESULTS: Transfection of the lentiviral vector FABP5-shRNA obviously reduced FABP5 expression in the HepG2 cells. Tumor formation was all positive in the 3 groups of the nude mice inoculated with the tumor cells. Compared with normal control group and negative control group, the tumor growth slowed significantly in experimental group with smaller volume and weight. FABP5 expression in the transplanted tumor tissues was significantly down-regulated at mRNA and protein levels in experimental group as compared with normal control group and negative control group.CONCLUSION: RNAi-induced down-regulation of FABP5 effectively inhibits the growth of transplanted hepatocellular carcinoma, suggesting that FABP5 gene may be an effective target for gene therapy in treating liver cancer.